A new method for measurement of total plasma PCSK9: Clinical applications

Journal of Lipid Research

Volumn 51, Issue 1, 2010, Pages 140-149

  Dubuc, Geneviève ^a   Tremblay, Michel ^a   Paré, Guillaume ^c   Jacques, Hélène ^a   Hamelin, Josée ^a   Benjannet, Suzanne ^a   Boulet, Lucie ^a   Genest, Jacques ^b   Bernier, Lise ^a   Seidah, Nabil G ^a   Davignon, Jean ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular disease; ELISA; Hypercholesterolemia; Hypocholesterolemia; LDL cholesterol; Novel natural mutation; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMA PROTEIN; PRAVASTATIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 PROTEIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE INCREASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEQUENCE ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 73149094934     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M900273-JLR200     Document Type: Article

References (49)

1. Goldstein, J. L., H. H. Hobbs, and M. S. Brown. Familial hypercholesterolemia. 2001. In The metabolic and molecular bases of inherited disease. Valle D., C. R. Scriver A. L. Beaudet, W. S. Sly, B. Childs, and B. Volgestein, editors. Chapter 120, 8th edition. McGraw Hill, New York. 2863-2913.
2. Innerarity, T. L., K. H. Weisgraber, K. S. Arnold, R. W. Mahley, R. M. Krauss, G. L. Vega, and S. M. Grundy. 1987. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc. Natl. Acad. Sci. USA. 84: 6919-6923.
3. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34: 154-156.
4. Seidah, N. G., S. Benjannet, L. Wickham, J. Marcinkiewicz, S. B. Jasmin, S. Stifani, A. Basak, A. Prat, and M. Chretien. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA. 100: 928-933.
5. Seidah, N. G., and A. Prat. 2007. The proprotein convertases are potential targets in the treatment of dyslipidemia. J. Mol. Med. 85: 685-696.
6. Nassoury, N., D. A. Blasiole, O. A. Tebon, S. Benjannet, J. Hamelin, V. Poupon, P. S. McPherson, A. D. Attie, A. Prat, and N. G. Seidah. 2007. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 8: 718-732.
7. Zhang, D. W., R. Garuti, W. J. Tang, J. C. Cohen, and H. H. Hobbs. 2008. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 105: 13045-13050.
8. Kwon, H. J., T. A. Lagace, M. C. McNutt, J. D. Horton, and J. Deisenhofer. 2008. Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. USA. 105: 1820-1825.
9. Park, S. W., Y. A. Moon, and J. D. Horton. 2004. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279: 50630-50638.
10. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M. C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/ PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279: 48865-48875.
11. Maxwell, K. N., E. A. Fisher, and J. L. Breslow. 2005. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA. 102: 2069-2074.
12. Cameron, J., O. L. Holla, T. Ranheim, M. A. Kulseth, K. E. Berge, and T. P. Leren. 2006. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 15: 1551-1558.
13. Zaid, A., A. Roubtsova, R. Essalmani, J. Marcinkiewicz, A. Chamberland, J. Hamelin, M. Tremblay, H. Jacques, W. Jin, J. Davignon, et al. 2008. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 48: 646-654.
14. Lagace, T. A., D. E. Curtis, R. Garuti, M. C. McNutt, S. W. Park, H. B. Prather, N. N. Anderson, Y. K. Ho, R. E. Hammer, and J. D. Horton. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. J. Clin. Invest. 116: 2995-3005.
15. Luo, Y., L. Warren, D. Xia, H. Jensen, T. Sand, S. Petras, W. Qin, K. S. Miller, and J. Hawkins. 2009. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J. Lipid Res. 50: 1581-1588.
16. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y. A. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA. 102: 5374-5379.
17. Benjannet, S., D. Rhainds, J. Hamelin, N. Nassoury, and N. G. Seidah. 2006. The proprotein convertase PCSK9 is inactivated by furin and/or PC5/ 6A: Functional consequences of natural mutations and post-translational modifications. J. Biol. Chem. 281: 30561-30572.
18. Zhao, Z., Y. Tuakli-Wosornu, T. A. Lagace, L. Kinch, N. V. Grishin, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79: 514-523.
19. Kotowski, I. K., A. Pertsemlidis, A. Luke, R. S. Cooper, G. L. Vega, J. C. Cohen, and H. H. Hobbs. 2006. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78: 410-422.
20. Abifadel, M., J. P. Rabes, C. Boileau, and M. Varret. 2007. [After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9.] Ann. Endocrinol. (Paris). 68: 138-146.
21. Timms, K. M., S. Wagner, M. E. Samuels, K. Forbey, H. Goldfine, S. Jammulapati, M. H. Skolnick, P. N. Hopkins, S. C. Hunt, and D. M. Shattuck. 2004. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114: 349-353.
22. Naoumova, R. P., I. Tosi, D. Patel, C. Neuwirth, S. D. Horswell, A. D. Marais, C. van Heyningen, and A. K. Soutar. 2005. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler. Thromb. Vasc. Biol. 25: 2654-2660.
23. Cohen, J. C., E. Boerwinkle, T. H. Mosley, Jr., and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
24. Hooper, A. J., A. D. Marais, D. M. Tanyanyiwa, and J. R. Burnett. 2007. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 193: 445-448.
25. Horton, J. D., J. C. Cohen, and H. H. Hobbs. 2009. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50: S172-S177.
26. Maxwell, K. N., R. E. Soccio, E. M. Duncan, E. Sehayek, and J. L. Breslow. 2003. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44: 2109-2119.
27. Horton, J. D., N. A. Shah, J. A. Warrington, N. N. Anderson, S. W. Park, M. S. Brown, and J. L. Goldstein. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA. 100: 12027-12032.
28. Dubuc, G., A. Chamberland, H. Wassef, J. Davignon, N. G. Seidah, L. Bernier, and A. Prat. 2004. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis- regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24: 1454-1459.
29. Mayne, J., T. Dewpura, A. Raymond, M. Cousins, A. Chaplin, K. A. Lahey, S. A. Lahaye, M. Mbikay, T. C. Ooi, and M. Chretien. 2008. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 7: 22.
30. Lambert, G., N. Ancellin, F. Charlton, D. Comas, J. Pilot, A. Keech, S. Patel, D. R. Sullivan, J. S. Cohn, K. A. Rye, et al. 2008. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin. Chem. 54: 1038-1045.
31. Careskey, H. E., R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao, and R. J. Konrad. 2008. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49: 394-398.
32. Demacker, P. N., M. J. Veerkamp, S. J. Bredie, S. M. Marcovina, J. de Graaf, and A. F. Stalenhoef. 2000. Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis. 153: 483-490.
33. Mayer, G., S. Poirier, and N. G. Seidah. 2008. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J. Biol. Chem. 283: 31791-31801.
34. Yue, P., M. Averna, X. Lin, and G. Schonfeld. 2006. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum. Mutat. 27: 460-466.
35. Seidah, N. G., G. Mayer, A. Zaid, E. Rousselet, N. Nassoury, S. Poirier, R. Essalmani, and A. Prat. 2008. The activation and physiological functions of the proprotein convertases. Int. J. Biochem. Cell Biol. 40: 1111-1125.
36. Lambert, G. 2007. Unravelling the functional significance of PCSK9. Curr. Opin. Lipidol. 18: 304-309.
37. Lakoski, S. G., T. A. Lagace, J. C. Cohen, J. D. Horton, and H. H. Hobbs. 2009. Plasma levels of PCSK9 in a large multiethnic population. J. Clin. Endocrinol. Metab. In press.
38. Le May, C., S. Kourimate, C. Langhi, M. Chetiveaux, A. Jarry, C. Comera, X. Collet, F. Kuipers, M. Krempf, B. Cariou, et al. 2009. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler. Thromb. Vasc. Biol. In press.
39. Alborn, W. E., G. Cao, H. E. Careskey, Y. W. Qian, D. R. Subramaniam, J. Davies, E. M. Conner, and R. J. Konrad. 2007. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin. Chem. 53: 1814-1819.
40. Mayne, J., A. Raymond, A. Chaplin, M. Cousins, N. Kaefer, C. Gyamera-Acheampong, N. G. Seidah, M. Mbikay, M. Chretien, and T. C. Ooi. 2007. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem. Biophys. Res. Commun. 361: 451-456.
41. Wilhelmsen, L., S. Johansson, A. Rosengren, I. Wallin, A. Dotevall, and G. Lappas. 1997. Risk factors for cardiovascular disease during the period 1985-1995 in Goteborg, Sweden. The GOT-MONICA Project. J. Intern. Med. 242: 199-211.
42. Cunningham, D., D. E. Danley, K. F. Geoghegan, M. C. Griffor, J. L. Hawkins, T. A. Subashi, A. H. Varghese, M. J. Ammirati, J. S. Culp, L. R. Hoth, et al. 2007. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14: 413-419.
43. Abifadel, M., L. Bernier, G. Dubuc, G. Nuel, J. P. Rabes, J. Bonneau, A. Marques, M. Marduel, M. Devillers, D. Erlich, et al. 2008. A PCSK9 variant and familial combined hyperlipidemia. J. Med. Genet. 45: 780-786.
44. Allard, D., S. Amsellem, M. Abifadel, M. Trillard, M. Devillers, G. Luc, M. Krempf, Y. Reznik, J. P. Girardet, A. Fredenrich, et al. 2005. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum. Mutat. 26: 497-506.
45. Berge, K. E., L. Ose, and T. P. Leren. 2006. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 26: 1094-1100.
46. Gouni-Berthold, I., H. K. Berthold, H. Gylling, M. Hallikainen, E. Giannakidou, S. Stier, Y. Ko, D. Patel, A. K. Soutar, U. Seedorf, et al. 2008. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis. 198: 198-207.
47. Kourimate, S., C. Le May, C. Langhi, A. L. Jarnoux, K. Ouguerram, Y. Zair, P. Nguyen, M. Krempf, B. Cariou, and P. Costet. 2008. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J. Biol. Chem. 283: 9666-9673.
48. Mikhailidis, D. P., G. C. Sibbring, C. M. Ballantyne, G. M. Davies, and A. L. Catapano. 2007. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr. Med. Res. Opin. 23: 2009-2026.
49. Chan, J. C., D. E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, et al. 2009. From the cover: a proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA. 106: 9820-9825.